Antiangiogenic therapy can normalize blood vessels, thereby allowing programmed cell death protein 1(PD‐1) inhibitors or programmed cell death ligand 1 (PD‐L1) inhibitors to enter the tumor microenvironment. The gene discussed is CD274; the disease is neoplasm.